Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
Returns on capital
Mereo BioPharma Group plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-102.4%
avg 40.6%
ROIC
-91.5%
avg -48.9%
ROA
-91.2%
avg -58.2%
Analysis
ROA is currently the strongest return metric at -91.2% versus its period average of -58.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Denise Scots-Knight | Co-Founder, Chief Executive Officer & Executive Director | USD 686.84K | 67 | 345.00K | 0.22% |
Charles Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | USD 536.44K | 57 | 105.25K | 0.07% |
Christine Fox | Chief Financial Officer | USD 497.2K | 45 | — | — |
Jackie Parkin | Senior Vice President & Therapeutic Head | — | 68 | — | — |
John A. Lewicki | Chief Scientific Officer | — | 74 | 46.64K | 0.03% |
Bo Kara | Senior Vice President and Head of Pharmaceutical Development & CMC | — | — | — | — |
Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | — | 55 | 61.25K | 0.04% |
Bal Lally | VP & Head of HR | — | — | — | — |
Bharti Navsariwala | VP & Head of Regulatory Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Sep 26, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +179.9% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +179.9% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Mereo BioPharma Group plc compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MREO's management, answered from reported figures.
Who manages MREO?
Mereo BioPharma Group plc (MREO) lists 9 active executives. The top listed executive is Denise Scots-Knight, Co-Founder, Chief Executive Officer & Executive Director.
Are MREO insiders buying or selling?
Recent insider activity shows net selling of $2.44M.
Continue the stock analysis
Jump to another research area for this company.